The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.50
Bid: 1.40
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.20 (14.286%)
Open: 1.50
High: 1.50
Low: 1.50
Prev. Close: 1.50
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

17 Jan 2018 15:52

RNS Number : 1812C
Physiomics PLC
17 January 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

PHYSIOMICS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Jason Cropper

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

15 January 2018

6. Date on which issuer notified (DD/MM/YYYY):

15 January 2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.4%

58,785,394

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

2,000,000

3.4%

SUBTOTAL 8. A

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

Preston

Date of completion

15 January 2018

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEDLFFVFFEBBF
Date   Source Headline
26th Apr 201811:06 amRNSContract Award
6th Apr 20182:40 pmRNSDirector/PDMR Shareholding
4th Apr 20187:00 amRNSPhysiomics to Present at AACR Annual Meeting
27th Mar 20185:23 pmRNSIssue of Options
14th Mar 20187:00 amRNSAward of New Innovate UK Grant
12th Mar 20187:00 amRNSCompletion of Innovate UK Grant Project
19th Feb 20187:00 amRNSInterim Results Statement
9th Feb 20187:00 amRNSContract Award
26th Jan 20187:00 amRNSNew Major Pharmaceutical Client
25th Jan 20181:34 pmRNSHolding(s) in Company
24th Jan 20188:46 amRNSHolding(s) in Company
19th Jan 201810:20 amRNSHolding(s) in Company
17th Jan 20183:52 pmRNSHolding(s) in Company
13th Dec 20172:06 pmRNSResult of AGM
12th Dec 201710:17 amRNSDirector Dealing
6th Dec 20173:00 pmRNSIssue of Equity
30th Nov 20171:38 pmRNSShare Price Movement
28th Nov 20177:00 amRNSClinical Project Completion and Services Agreement
9th Nov 20177:00 amRNSDispatch of Annual Report and Shareholder Circular
16th Oct 20177:00 amRNSFinal Results
2nd Oct 20177:00 amRNSCompany Update
31st Jul 20177:00 amRNSTwo New Pre-Clinical Contracts
6th Jun 20177:00 amRNSPhysiomics to Attend PAGE 2017
24th May 20177:00 amRNSUpdate: Two Further Extension Projects
5th May 20177:00 amRNSPhysiomics to Present at BioTrinity 2017
24th Mar 201711:15 amRNSInterim Results Statement
11th Jan 20177:00 amRNSCompany Update
6th Jan 20177:00 amRNSConfirmation of Award of Innovate UK Grant
22nd Dec 20163:31 pmRNSDirector Dealing
22nd Dec 20167:00 amRNSIssue of Options
16th Dec 20161:00 pmRNSResult of AGM
5th Dec 20167:00 amRNSPayment for in-silico modelling of inhibitor
23rd Nov 20167:00 amRNSPosting of Financial Results and Notice of AGM
22nd Nov 20167:00 amRNSProvisional Award of Innovate UK Grant
27th Oct 20163:00 pmRNSFinal Results for the year ended 30 June 2016
26th Oct 20167:00 amRNSPresentation at Conference on Pharmacometrics
25th Oct 20167:00 amRNSDirectorate Change
28th Sep 20167:00 amRNSAdvisor Changes
21st Sep 20167:00 amRNSPlacing and Update on Acquisition
7th Sep 201612:19 pmRNSResult of GM
22nd Aug 20167:00 amRNSNotice of General Meeting
18th Aug 20167:00 amRNSSigning of Share Purchase Agreement with BioMoti
16th Aug 20161:05 pmRNSAdvisor Changes
16th May 20167:00 amRNSExtensions for Virtual Tumour Project
3rd May 20167:00 amRNSAppointment of part-time Head of Finance
18th Apr 20169:02 amRNSPhysiomics Appoints New Chief Executive Officer
6th Apr 201610:15 amRNSVirtual Tumour Developments Presentation at AACR
4th Apr 201612:12 pmRNSNew Speciality Pharma Customer for new Indication
31st Mar 20167:01 amRNSInterim Results Statement
31st Mar 20167:00 amRNSHeads of Terms with BioMoti and Board Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.